Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer
Journal of Gastric Cancer · 2025 · 25 (2) · 303
DOI: 10.5230/jgc.2025.25.e2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastric Cancer, 2025. Verfasst von Seung-Myoung Son und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Claudins, Adenocarcinoma, Biomarkers, Tumor. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NRF, National Research Foundation of Korea.
Abstract (Originalsprache)
PURPOSE: Claudin 18.2 (CLDN18.2) has emerged as a promising therapeutic target for CLDN18.2-expressing gastric cancer (GC). We sought to examine the heterogeneity of CLDN18.2 expression between primary GC (PGC) and metastatic GC (MGC) using various scoring methods. MATERIALS AND METHODS: We retrospectively analyzed data from 102 patients with pathologically confirmed paired primary and metastatic gastric or gastroesophageal junction adenocarcinomas. CLDN18.2 expression was evaluated through immunohistochemistry on formalin-fixed paraffin-embedded tissue samples. We assessed CLDN18.2 positivity using multiple scoring approaches, including the immunoreactivity score, H-score, and the percentage of tumor cells showing moderate-to-strong staining intensity. We analyzed the concordance rates between PGC and MGC and the association of CLDN18.2 positivity with clinicopathological features. RESULTS: CLDN18.2 positivity varied from 25% to 65% depending on the scoring method, with PGC consistently showing higher expression levels than MGC. Intratumoral heterogeneity was noted in 25.5% of PGCs and 19.6% of MGCs. Intertumoral heterogeneity, manifesting as discordance in CLDN18.2 positivity between PGC and MGC, was observed in about 20% of cases, with moderate agreement across scoring methods (κ=0.47 to 0.60). In PGC, higher CLDN18.2 positivity correlated with synchronous metastasis, presence of peritoneal metastasis, poorly differentiated grade, and biopsy specimens. In MGC, positivity was associated with synchronous metastasis, presence of peritoneal metastasis, and metastatic peritoneal tissues. CONCLUSIONS: CLDN18.2 expression demonstrates significant heterogeneity between PGC and MGC, with a 20% discordance rate. Comprehensive tissue sampling and reassessment of CLDN18.2 status are crucial, especially before initiating CLDN18.2-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
- Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
- Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.
- Department of Surgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
- Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea. hyesukhan@chungbuk.ac.kr.
ORCID-Profile: Seung-Myoung Son, Chang Gok Woo, Ok-Jun Lee, Yong-Pyo Lee, Hongsik Kim, Hee Kyung Kim, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Dae Hoon Kim, Hyo Yung Yun, Hye Sook Han
Förderung
- NRF
- National Research Foundation of Korea
Zitieren
APA
Son, S. M., Woo, C. G., Lee, O. J., Lee, S. K., Cho, M., Lee, Y. P., Kim, H., Kim, H. K., Yang, Y., Kwon, J., Lee, K. H., Kim, D. H., Yun, H. Y., & Han, H. S. (2025). Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer. Journal of Gastric Cancer, 25(2), 303. https://doi.org/10.5230/jgc.2025.25.e2
Vancouver
Son SM, Woo CG, Lee OJ, Lee SK, Cho M, Lee YP, et al. Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer. Journal of Gastric Cancer. 2025;25(2):303. doi:10.5230/jgc.2025.25.e2
BibTeX
@article{Son2025,
author = {Son, Seung-Myoung and Woo, Chang Gok and Lee, Ok-Jun and Lee, Sun Kyung and Cho, Minkwan and Lee, Yong-Pyo and Kim, Hongsik and Kim, Hee Kyung and Yang, Yaewon and Kwon, Jihyun and Lee, Ki Hyeong and Kim, Dae Hoon and Yun, Hyo Yung and Han, Hye Sook},
title = {Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer},
journal = {Journal of Gastric Cancer},
year = {2025},
volume = {25},
number = {2},
pages = {303},
doi = {10.5230/jgc.2025.25.e2}
}
EUVIMED